Arvinas filed Thursday to raise as much as $100 million in an initial public offering of stock, with the New Haven company developing novel treatments for cancer and other conditions. Only in April, Arvinas had secured $55 million in fresh funding through a private issuance of equity shares, with the company employing 70 people and listing 10 open jobs. The company has collaborations with Pfizer, Genentech and Hoffman-La Roche that have generated proceeds to date of $73.5 million, with the possibility for as much as $1.4 billion through future royalties and other milestone payments. As of June 30, Arvinas reported an accumulated deficit of $160 million, including $12 million in the first six month of this year.
from Business https://www.ctpost.com/business/article/Years-after-early-kiss-of-death-studies-13196857.php
No comments:
Post a Comment